TrialBridgeNCT06586632
The Steno Free Trial: AID to Adults with New-onset of Type 1 Diabetes
Not Yet Recruiting · Not Applicable · University of Aarhus · registry updated 2024-09-19
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Since the introduction of insulin therapy 100 years ago, significant progress has continuously been made in the treatment of people with type 1 diabetes. In the last 10 years, the focus has largely been on technology, and the introduction of automated insulin delivery (AID) systems has revolutionized the treatment of type 1 diabetes. AID is an automated system that works by enabling the insulin pump and continuous glucose monitor (CGM) to communicate with each other, automatically adjusting the subcutaneous insulin dosage according to blood glucose levels. AID technology is predominantly used for individuals with long duration of type 1 diabetes, and due to economic limitations in access to the treatment, it is especially used for those with treatment-related challenges in diabetes regulation. The aim of the Steno Free trials is to investigate whether AID technology combined with on-demand consultations for adults with newly diagnosed type 1 diabetes, compared to conventional standard treatment with a CGM after 1 year of treatment, leads to: 1. less diabetes distress, improved quality of life, and increased health literacy, 2. better diabetes regulation, 3....
Inclusion
- new-onset of Type 1 diabetes with positive auto-antibodies
Exclusion
- negative auto-antibodies,
- uncertainty about the type 1 diabetes diagnosis
- ongoing cancer or other acute/chronic severe illnesses that could potentially hinder participation and compliance in the project (determined by the PI)